Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The decision aligns with the company's Code of Conduct for Prohibition of Insider Trading and SEBI regulations. The specific date for the Board Meeting to declare these financial results will be communicated separately.

Solara Active Pharma Sciences Ltd has responded to an email from the BSE dated June 10, 2026, regarding a significant increase in trading volume for its securities. The company clarified that it has complied with all disclosure requirements under SEBI regulations and has not withheld any material information that could impact the stock's price or volume behavior. This statement aims to assure the exchange and investors of the company's transparency and adherence to listing norms.

Solara Active Pharma Sciences Ltd has announced a special window for the transfer and dematerialisation of physical securities sold or purchased before April 1, 2019. This window, open from February 5, 2026, to February 4, 2027, aims to facilitate investors in securing their rights. Transferred securities will be mandatorily dematerialised and subject to a one-year lock-in period. The company also reminded shareholders about SEBI's mandate for furnishing PAN, KYC, and nomination details for physical securities, providing relevant forms and contact information for assistance.

Solara Active Pharma Sciences Ltd. has released a monitoring agency report by CRISIL Ratings Limited for the quarter ended March 31, 2026, regarding the utilization of proceeds from its Rights Issue. The report confirms no deviation in the use of issue proceeds from the stated objectives in the Letter of Offer. The Rights Issue took place between May 28, 2024, and June 11, 2024, with an issue size of ₹449.95 crore.

Solara Active Pharma Sciences Ltd. has announced the approval and adoption of a Board Evaluation Policy and amendments to its Whistle Blower Policy. These changes are in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The updated policies are available on the company's website.

Solara Active Pharma Sciences Limited reported no deviation or variation in the use of proceeds raised through its Rights Issue for the quarter ended March 31, 2026. This confirmation complies with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee reviewed and approved the statement of utilization of proceeds without any comments.

Solara Active Pharma Sciences Ltd has re-appointed Mr. M K. Suryanarayanan as Cost Auditor and M/s. Grant Thornton Bharat LLP as Internal Auditor for the financial year 2026-27. The appointments were approved at the Board of Directors meeting held on May 15, 2026, as per Regulation 30 of the SEBI Listing Regulations.

Solara Active Pharma Sciences Ltd. announced the conversion of partly paid-up rights equity shares into fully paid-up equity shares following the receipt of ₹1,29,94,28,775.00 related to the Second & Final Call. The Rights Issue Committee approved the conversion of 1,15,50,478 partly paid-up shares into fully paid-up shares. Post-conversion, the paid-up capital of the company is ₹47,98,12,464.50.

Solara Active Pharma Sciences Ltd reported strong Q4'26 results, driven by base business momentum despite headwinds in the commodity Ibuprofen business. Overall Q4'26 performance reflects a sequential growth of 12% and YoY growth of 40%, achieving the highest revenue, gross margin, and EBITDA in the last eight quarters. The base business demonstrated superior profitability with a ~26% EBITDA margin and ~54% gross margin. The company has appointed bankers to evaluate strategic options for the Ibuprofen business due to persistent weak profitability.

Solara Active Pharma Sciences Ltd. has announced the approval of audited standalone and consolidated financial results for the year ended March 31, 2026. The decision was made during a board meeting held on May 15, 2026, following the recommendation of the Audit Committee. The board also took on record the unmodified opinions from the Statutory Auditors, M/s. Deloitte Haskins & Sells LLP, regarding the audited financial results. The results are available on the company's website.